TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Collplant Holdings ( (CLGN) ) is now available.
On October 16, 2025, CollPlant Biotechnologies announced the development of a first-of-its-kind fully humanized 3D bioprinted human skin model by Mayo Clinic researchers, utilizing CollPlant’s rhCollagen-based bioink. This model, which serves as an alternative to animal testing, has significant implications for cosmetic and pharmaceutical testing, disease modeling, and drug development, offering a sustainable and ethical solution while advancing regenerative medicine.
The most recent analyst rating on (CLGN) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
Collplant Holdings’ overall stock score is primarily impacted by its poor financial performance, characterized by significant revenue and cash flow challenges. While there is some technical strength, the negative valuation metrics further weigh down the score, indicating a high-risk investment.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on developing innovative solutions using its proprietary recombinant human collagen (rhCollagen). The company specializes in 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, leveraging plant-based genetic engineering technology.
Average Trading Volume: 105,498
Technical Sentiment Signal: Sell
Current Market Cap: $30.52M
Learn more about CLGN stock on TipRanks’ Stock Analysis page.